Yufan, Abound Bio to develop CAR T cell therapies

By The Science Advisory Board staff writers

September 16, 2020 -- Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer targets.

The three-year deal covers incorporating antibodies to 10 cancer targets into a HPK1- (hematopoietic progenitor kinase 1) inhibited CAR T-cell platform. HPK1 promotes T-cell exhaustion, which is a strategy that can be used to improve CAR T-cell immunotherapy.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.